A novel ultraviolet (UV) method, distinguished by its rapidity, sensitivity, simplicity, and cost-effectiveness, was prepared for the quantification of Rebamipide in both scaleup and pharmaceutical formulations. The absorbance of Rebamipide was measured relatively in ethanol at a new wavelength (λmax 325). The method demonstrated a linearity range spanning from 5 to 60 μg/ml, with a regression equation represented as relative absorbance 0.016x concentration in μg/ml + 0.1621, and a regression coefficient of 0.998. Validation procedures were conducted per International Council for Harmonisation (ICH) and United States Pharmacopeia (USP) specifications, affirming the method's accuracy, precision, and reproducibility (relative standard deviation <2.0%). This criterion is effective for the estimation of Rebamipide across various dosage forms, yielding results in alignment with label claims. Its validation provides a prompt, cost-effective, and accurate approach to assess Rebamipide potency and consistency in pharmaceutical products, thereby enhancing healthcare standards and ensuring patient safety.
No takes yet. Share an insight, caveat, or question.
Ujjwal Nautiyal (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: